Yaroslav Dziublyk

Dr. Yaroslav Dziublyk

National institute of pulmonology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Volodymyr GavrysyukVolodymyr Gavrysyuk
Volodymyr Gavrysyuk
IMIevgeniia Merenkova
Ievgeniia Merenkova
YDYaroslav Dziublyk
Yaroslav Dziublyk
NMNataliia Morska
Nataliia Morska
NPNataliia Pendalchuk
Nataliia Pendalchuk
NVNataliia Vlasova
Nataliia Vlasova
Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate. Purpose: The aim of our study was to evaluate primary and long-term outcomes of using MTX and MP in patients with pulmonary sarcoidosis. Methods: A total of 143 patients with newly diagnosed pulmonary sarcoidosis, verified by high-resolution computed tomography (CT) data, were examined. Corticosteroid (CS) therapy was used in 97 patients using MP at a dose of 0.4 mg/kg body weight for 4 weeks, followed by a dose reduction to 0.1 mg/kg by the end of the sixth month. The total duration of CS therapy was 12 months on average. Forty-six patients were treated with MTX at a dose of 10 mg/week (28) and 15 mg/week (18) per os for 6 to 12 months. The study of the relapse rate was conducted within 12 months after the CT data normalization in 60 patients after CS therapy and in 24 after MTX treatment. Results: MP treatment was successfully completed in 68 (70.1%), and MTX in 29 (60.4%) patients. In five MP patients (5.2%) and in five (10.9%) MTX, treatment was discontinued due to serious side effects. In seven (7.2%) MP patients and ten (21.7%) MTX patients, treatment required additional therapy due to the lack of efficacy. Progression with MP treatment (17–17.5%) was more common than with MTX (2–4.3%; Chi square = 4.703, p = 0.031). Relapses after MP therapy were observed in 26 (43.3%) patients, and after MTX therapy in 2 (8.3%; Chi square = 9.450, p = 0.003). Conclusion: In patients with pulmonary sarcoidosis, MTX monotherapy does not differ significantly from MP monotherapy in terms of the level of efficacy and the rate of serious side effects. Increasing the MTX dose from 10 to 15 mg/week accelerates the rate of regression of sarcoidosis, improves treatment efficacy, and does not affect the rate of serious side effects. When using MTX, there is a significant decrease in the incidence of treatment resistance and the relapse rate.

22 January 2024 in Innovative Biosystems and Bioengineering
Verified
Journal Article
Open access
PDF file
OYOleh Yakovenko
Oleh Yakovenko
SSSerhii Soloviov
Serhii Soloviov
MSMykhailo Smetiukh
Mykhailo Smetiukh
OKOleksandr Khanin
Oleksandr Khanin
EKEduard Khodosh
Eduard Khodosh
NSNataliia Surtaieva
Nataliia Surtaieva
Background. Today's latest infection, COVID-19, remains an urgent problem of the Ukrainian healthcare system, which requires further efforts to develop effective treatment strategies, especially considering the potential exacerbation of comorbidities. Objective. Develop and approve a multivariate model of the effectiveness of the treating mild COVID-19 in patients with comorbidities, using Aminocaproic acid in comparison to nirmatrelvir/ritonavir and symptomatic therapy as examples. Methods. The modeling was based on the results of a clinical study involving three groups of patients with mild COVID-19. Clinical symptoms and quality of life were dynamically evaluated through standardized questionnaires. Regression analysis was used to analyze the dynamics of clinical symptoms and identify general patterns and their correlation with quality of life. Results. Modeling the dynamics of individual clinical symptoms allowed for the examination of recovery trends in mild COVID-19 patients under different drug treatments. Aminocaproic acid demonstrated a faster alleviation of primary respiratory symptoms compared to alternative treatments. Regression analysis highlighted that cough, sore throat, and general fatigue exert the most significant negative impact on the quality of life. These symptoms contribute to the decline in both physical and psychological health and limit activity during the disease course. Conclusions. This study presents a novel, multidimensional model considering both the dynamics of individual clinical symptoms and patients' quality of life. The developed model was validated with retrospective data from mild COVID-19 patients with comorbidities. A multidimensional simulation of the clinical effectiveness of the use of aminocaproic acid, nirmatrelvir/ritonavir, or symptomatic treatment supports the preferential use of aminocaproic acid over other treatment methods. The quality-of-life modeling has enhanced our systematic understanding of the interplay between a set of clinical symptoms and overall patient condition, providing a rational foundation for treatment and care decisions.

8 September 2024 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
VKV.M. Kovalenko
V.M. Kovalenko
МКМ.о. Коrzh
М.о. Коrzh
TRTronko
Tronko
IGI.YU. Golovach
I.YU. Golovach
TKT.A. Karasevska
T.A. Karasevska
Introduction. Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disease that develops as a result of glucocorticoid (GC) use, is one of the most frequent causes of secondary osteoporosis, leads to an increase in the risk of low-energy fractures, disability and mortality of GC users. Despite the few stu­dies conducted in Ukraine on the epidemiology and treatment of GIOP, there have been no national recommendations for its ma­nagement until now, which has become the background for their creation. The purpose was to develop national guidelines for the diagnosis, prevention, and treatment of GIOP based on the analytical analysis of modern literary sources to improve the awareness of the medical community of Ukraine, improve management, and reduce the socio-economic burden of the disease. Materials and ­methods. A group of 18 experts, leading Ukrainian scientists in various fields, was created to develop the guideline. An analysis of current literary sources on epidemiology, risk factors, diagnosis, prevention and treatment of GIOP, and monitoring of the effectiveness and safety of its treatment was carried out. Evidence was synthesized ­using the GRADE system, and a critical assessment of the quality of the recommendations was carried out using the AGREE II tool. ­Results. The guideline consists of 12 provisions on screening, diagnosis, prevention, and treatment of GIOP. The authors emphasized the need to increase the awareness of the medical community of Ukraine regarding the problem, as well as patients regarding the possible side effects of GC. They presented the features of the clinical assessment of the osteoporotic fracture risk in GC users, as well as modern and available in Ukraine methods of diagnosis and treatment of GIOP. Conclusion. The first Ukrainian guideline for screening, diagnosis, prevention, and treatment of GIOP is an important national tool for its management, which is recommended by the Board of the Ukrainian Association of Osteoporosis for use in practical health care by doctors of various specialties.

24 February 2025 in Archives of Osteoporosis
Verified
Journal Article
Closed access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
VKV. M. Kovalenko
V. M. Kovalenko
MКM. O. Кorzh
M. O. Кorzh
MOMaryan Ostafiychuk
Maryan Ostafiychuk
IGI. Yu. Golovach
I. Yu. Golovach
TKT. A. Karasevska
T. A. Karasevska

28 June 2023 in EMERGENCY MEDICINE
Verified
Journal Article
Open access
PDF file
OYO.K. Yakovenko
O.K. Yakovenko
SGS.L. Griff
S.L. Griff
SHS. Hoffmann
S. Hoffmann
ОKО.H. Khanin
О.H. Khanin
EKE.M. Khodosh
E.M. Khodosh
YDYaroslav Dziublyk
Yaroslav Dziublyk
Background. The study of pathogenesis and the search for factors that lead to mortality from severe COVID-19 and disability due to post-COVID interstitial lung disease with permanent physiological and functional deficits is an urgent and unsolved problem today. The purpose was to investigate lung histopathology in patients who died of severe COVID-19 in the acute and post-acute period of the disease, and to determine the significance of histological changes in the lung parenchyma depending on gender, duration of the disease, and the use or non-use of respiratory support. Materials and methods. The study included the results of lung sample analysis in patients with severe COVID-19 who died from June to December 2020 (n = 10) and from January to December 2021 (n = 21). An autopsy was performed in 61.3 % of patients who died in the acute period of the disease (up to the 28th day), and in 38.7 % of those who died in the post-acute period (day 29–84). Respiratory support was used in 58 % (n = 18) of cases in the acute period. Results. Patients with severe COVID-19 who did not survive the acute period of the disease (its average duration was 17.31 days, the average age of the deceased was 66.1 years) and the post-acute period (the average duration of the disease was 43.22 days, the average age of the deceased was 67.8 years) had the following: the presence of hyaline membranes in 70.9 %, capillary stasis in 77.4 %, organizing pneumonia in 41.9 %, pulmonary fibrosis in 32.2 %, hemorrhages in 38.7 %, small vein thrombosis in 25.8 %, histospecific signs of bacterial and fungal co-infection in 16.1 and 3.2 %, respectively, diffuse alveolar damage in 90.3 % of cases (with acute fibrinous and organizing pneumonia in 9.6 %). Conclusions. The risk of capillary stasis is significantly higher in the post-acute than in the acute period of the disease (p = 1.7454). No statistically significant correlation was found between the acute (p = 0.359) and post-acute (p = 0.146) periods and the risk of pulmonary fibrosis. Also, no significant relationship was detected between the use of respiratory support and recorded pulmonary fibrosis in the acute (p = 0.238) and post-acute (p = 0.302) periods. It was found that the histopathological signs of hemorrhages in the lungs are the same in both periods compared to the small vein thrombosis whose risk in the acute period is significantly higher than in the post-acute one (p = 0.05). The risk of bacterial co-infection in the acute period of the disease is significantly lower than the probability of its absence (p = 0.001). The risk of a fatal outcome in the acute period of the disease among men is significantly higher than among women (p = 0.05), while in the post-acute period, there is no statistically significant dependence on gender.

25 May 2022 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
OYO.K. Yakovenko
O.K. Yakovenko
YDYaroslav Dziublyk
Yaroslav Dziublyk
MLM.I. Lynnyk
M.I. Lynnyk
BACKGROUND. Pneumonia resulting from SARS-CoV-2 infection is characterized by the development of certain radiological patterns such as “ground glass” and others, which can only be detected using high-resolution computed tomography (HRCT) of the chest. The use of CT to combat the coronavirus disease (COVID-19) pandemic varies worldwide. In scientific publications, there is no consensus on the information content of CT for COVID-19 pneumonia, the timing of its implementation at the onset of the disease and control examinations. The long-term consequences of the disease, the possibilities of software processing of CT images of the chest cavity in order to study the dynamics of the process, predict outcomes and evaluate the effectiveness of the therapy, have not been sufficiently studied. OBJECTIVE. To determine the possibilities of digital software processing to increase the information content of CT images and justify its use in determining the dynamics and stage of development of COVID-19 pneumonia. MATERIALS AND METHODS. For image analysis, we used the Dragonfly program, which was provided free of charge for non-commercial scientific research by Object Research Systems (Montreal, Canada). The program allows you to carry out segmentation, mathematical and statistical processing of images, to build conventional and segmented histograms. To use it, it is necessary to reformat DICOM files of CT into so-called raster files (TIFF, JPEG). Further analysis of images of CT slices is performed using gray scale (from 64 to 512 gradations), which correlates with density values on the Hounsfield scale, which allows you to more accurately determine the structure of the organ under study. RESULTS AND DISCUSSION. The analysis of CT for COVID-19 pneumonia with the “ground glass” pattern showed that standard densitometry does not allow to determine the morphofunctional difference between the studied areas of “ground glass” and to determine the stage of its development. The segmentation histogram based on digital software processing of the same “ground glass” areas of the patient with COVID-19 pneumonia has changed significantly with a clear definition of a significant difference in the density of the pattern in dynamics, on the basis of which it can be concluded that the patient is undergoing a process of recovery and COVID-19 pneumonia is at the resolution stage. CONCLUSIONS. Carrying out digital software image processing with a CT segmentation histogram allows you to determine the dynamics and stage of development of COVID-19 pneumonia, evaluate the effectiveness and need for therapeutic measures. In order to conduct an objective control of the inflammatory process in COVID-19 pneumonia, it is necessary to conduct a HRCT of the chest at discharge from the hospital, especially in patients who were treated in the intensive care unit. If there are significant changes, follow-up studies should be carried out after 3 and 6 months, or depending on clinical indications.